Oaktree Acquisition Corp. III Life Sciences 2025 Annual Report: Key Insights for Investors

Executive Summary

Oaktree Acquisition Corp. III Life Sciences (“the Company”) is a blank check company formed in June 2024, incorporated in the Cayman Islands, and focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company completed its IPO and is now listed on Nasdaq, offering Class A ordinary shares and redeemable warrants, but has not yet selected a business combination target. Its executive offices are located at 333 South Grand Avenue, 28th Floor, Los Angeles, CA 90071.

Key Points and Features

• IPO and Public Listing: The Company is publicly traded on Nasdaq under the symbols “OA” for units and Class A shares. The IPO raised substantial capital, with \$201.56 million available for business combinations as of December 31, 2025.
• Structure and Objectives: As a SPAC, Oaktree Acquisition Corp. III Life Sciences aims to acquire a target business with an enterprise value between \$500 million and \$1.5 billion, preferably within the life sciences and healthcare sectors.
• Management Expertise: The management team and board have significant experience in operating, growing, and investing in public and private healthcare companies, sourcing and structuring deals, and optimizing capital structures. Founders include Aman Kumar, Zaid Pardasani, and Mathew Pendo, all senior investment professionals at Oaktree.
• Shareholder Protections and Rights: Shareholders are granted the right to redeem their shares for cash upon completion of an initial business combination at a price equal to the trust account balance per share. Redemptions may be conducted via tender offer or proxy solicitation.
• Emerging Growth and Smaller Reporting Company Status: The Company benefits from reduced financial reporting and disclosure obligations, as permitted under the JOBS Act and Regulation S-K, including exemption from auditor attestation on internal controls and reduced executive compensation disclosures.
• Transfer Restrictions: Founder shares and private placement units are subject to strict transfer restrictions, preventing sales or transfers until certain milestones are met (e.g., 30 days post-business combination).
• Potential Additional Equity Issuance: The Company may issue additional Class A ordinary shares or preference shares in connection with business combinations or employee incentive plans, potentially diluting existing shareholders.
• Redemption and Shareholder Approval: Under Nasdaq rules, shareholder approval is required for business combinations involving significant equity issuances, substantial interest by directors/officers, or resulting in a change of control.

Important Issues for Shareholders

• No Operating History or Revenues: The Company currently has no operating history and has not generated revenues. Investors have no basis to evaluate its ability to achieve its business objectives.
• Forward-Looking Risks: The report includes numerous forward-looking statements, subject to risks including market volatility, liquidity, redemption levels, regulatory changes, and the ability to consummate a suitable business combination. Any failure to complete a business combination may result in liquidation.
• Potential Dilution: Issuance of additional shares, conversion of founder shares at ratios above one-to-one, or equity issuance at prices below market could materially dilute shareholder interests.
• Conflict of Interest Risks: Sponsors, directors, and officers may face conflicts of interest, especially since their investment is primarily in founder shares with no redemption rights, potentially influencing their decision-making regarding business combinations.
• Regulatory and Legal Factors: The Company must comply with SEC and Nasdaq regulations, including tender offer rules, proxy solicitation requirements, and reporting obligations. Any material changes or amendments to agreements with sponsors, officers, or directors can be made without shareholder approval, which may affect share value.
• Sponsor and Insider Transactions: Sponsors, directors, and officers may purchase public shares, warrants, or units outside the redemption process, potentially reducing public float and affecting share liquidity or price.
• Tax Exemption: The Company has received a tax exemption from the Cayman Islands government, ensuring no taxes on profits, income, or capital gains for 30 years from July 2024.

Potential Price-Sensitive Information

• Ability to Amend Key Agreements Without Shareholder Approval: The Company’s letter agreement with sponsors, officers, and directors may be amended or waived by the board without shareholder approval, potentially affecting founder shares and private placement units, and impacting share value.
• Possible Dilutive Events: Any issuance of additional shares or conversion of founder shares above one-to-one could dilute existing shareholders and impact share price.
• Sponsor and Insider Purchases: Sponsor, directors, and officers may purchase securities outside the redemption process, possibly affecting public float and liquidity, which could move share prices.
• Uncertainty and Risks: The Company emphasizes its lack of operating history and the risks associated with its search for a business combination. Any failure to identify a suitable target or complete a transaction could result in liquidation, materially affecting share value.
• Emerging Growth Company Considerations: Reduced disclosure obligations may make the Company less attractive to some investors, impacting trading volume and share price volatility.

Conclusion

Oaktree Acquisition Corp. III Life Sciences presents both opportunities and significant risks for investors. While the Company’s management expertise and capital raise position it as an attractive partner for a life sciences business combination, the lack of operating history, possibility of dilution, and potential for insider-driven transactions without shareholder approval are critical issues. Shareholders should closely monitor developments, as any announcement regarding a business combination, material amendments to insider agreements, or significant insider purchases of securities could rapidly impact share value.

Disclaimer

This article is based on the 2025 Annual Report of Oaktree Acquisition Corp. III Life Sciences. It is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information herein may be subject to change, and the Company’s forward-looking statements involve risks and uncertainties that could materially affect actual results.

View Oaktree Acquisition Corp. III Life Sciences Historical chart here